Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of
MRVI ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Maravai Lifesciences Holdings, Inc. Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of Calif
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Bronstein, Gewirtz & Grossman, LLC Is Investigating SoundHound AI, Inc. (SOUN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SoundHound AI, Inc. ("SoundHound" or "the Company") (NASDAQ:SOUN).
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XPEL, Inc. (XPEL) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Maravai LifeSciences (NASDAQ:MRVI) Hits New 12-Month Low Following Analyst Downgrade
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report)’s share price hit a new 52-week low on Tuesday after Bank of America lowered their price target on the stock from $9.00 to $8.00.
Hosted on MSN6d
Maravai LifeSciences Holdings, Inc. (MRVI) Acquires Officinae Bio to Enhance AI-Driven mRNA Development
In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against the ...
Morningstar2d
MRVI Class Action Notice: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Maravai LifeSciences Holdings, Inc. Investors
Case No. 25-cv-00499, on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) securities ...
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of some unusual options trading on Wednesday. Traders bought 1,002 put options on the stock. This represents an ...
TMCnet1d
Rosen Law Firm Urges Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Stockholders to Contact the Firm for Information About Their Rights
The Allegations: Rosen Law Firm is Investigating the Allegations that Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Misled Investors Regarding its Business Operations.
Morningstar2d
MRVI CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Maravai LifeSciences Holdings, Inc.
MRVI CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Maravai LifeSciences Holdings, Inc. The Law Offices of Frank R. Cruz announces that it has filed a ...
Maravai LifeSciences Postpones its Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...
Fintel on MSN7d
Baird Downgrades Maravai LifeSciences Holdings (MRVI)
Fintel reports that on February 26, 2025, Baird downgraded their outlook for Maravai LifeSciences Holdings (NasdaqGS:MRVI) ...
Maravai Lifesciences price target lowered to $8 from $9 at BofA
BofA lowered the firm’s price target on Maravai Lifesciences (MRVI) to $8 from $9 and keeps a Buy rating on the shares after the company ...